HLB Inc

HLB Inc's capital structure is characterized by a debt-to-equity ratio of 0.21, indicating a relatively conservative leverage position. The company holds 69.49 billion KRW in cash and equivalents, but this is offset by 104.58 billion KRW in long-term debt, resulting in a net cash position of -35.09 billion KRW. The current ratio of 1.48 suggests the company has sufficient short-term assets to cover its short-term liabilities. However, the operating cash flow of -68.82 billion KRW and free cash flow of -107.05 billion KRW indicate significant liquidity pressure.

Profitability metrics show a return on equity of -20.93% and a return on assets of -13.26%, both well below industry norms for medical equipment and supplies firms. The company reported a net loss of 103.26 billion KRW and an operating loss of 37.47 billion KRW in the latest period. These results suggest operational inefficiencies or market challenges that are eroding profitability.

Geographic and segment exposure data is not available in the current dataset, but the company's revenue concentration within a single business sector (Healthcare Services & Equipment) suggests limited diversification. This lack of diversification increases vulnerability to sector-specific risks such as regulatory changes or supply chain disruptions.

The company's growth trajectory is currently negative, with a net loss and declining cash flows. While the capital expenditure of -2.21 billion KRW indicates some investment in operations, the overall financial performance suggests a contraction in business activity. The absence of forward-looking guidance in the dataset makes it difficult to assess future growth potential.

Risk factors include medium liquidity risk due to negative operating and free cash flows. The company has a low dilution risk, but the negative net cash position after subtracting total debt raises concerns about its ability to meet long-term obligations. The ESG score of 61.70 and a B grade suggest moderate environmental, social, and governance performance.

Recent events and filings are not detailed in the current dataset, but the financial results indicate a challenging operating environment. The company may need to address its liquidity and profitability issues to stabilize its financial position.

Revenue grew 23.6% year-over-year to 84.2 billion KRW, indicating top-line expansion despite ongoing profitability challenges.

Operating income improved 15.4% year-over-year, suggesting some stabilization in core operational performance relative to the prior period.

The debt-to-equity ratio of 0.21 is below the cohort median of 0.2, indicating a relatively conservative leverage position.

Dilution risk is assessed as low, providing some protection for existing shareholders against immediate equity value erosion.

Operating and net margins rank in the bottom quartile of the medical equipment cohort, reflecting poor competitive positioning.

High credit risk and medium liquidity risk flags suggest potential difficulties in meeting financial obligations and maintaining operations.

Revenue KRW 69.83B; Operating income -KRW 103.54B.

• ▍Revenue KRW 69.83B
• ▍Operating income -KRW 103.54B
• ▍Net margin -140.5%